Presentation ESC 2022 Efficacy and Safety of the Oral Factor XIa Inhibitor, Asundexian, Added to Dual Antiplatelet Therapy After an Acute Myocardial Infarction Presenter: John H. Alexander August 28, 2022
News Conference News ESC 2022 Factor XIa Inhibitors Show Potential for Safer Anticoagulation After MI, Stroke Todd Neale August 28, 2022
News Daily News Diabetes Influences Relative Effects of Ticagrelor, Prasugrel in ACS: ISAR-REACT 5 Todd Neale October 09, 2020
News Conference News ACC 2020 Aspirin Okay for Up to 30 Days in A-fib Patients After ACS or PCI: AUGUSTUS Todd Neale April 03, 2020
News Daily News Retrospective Study Links Testosterone Therapy to Lower Mortality After MI, but Controversy Continues Marcus A. Banks July 31, 2019
News Daily News Stay Away From Warfarin-Based Triple Therapy in Patients With A-fib and CAD, Study Affirms Todd Neale October 03, 2018
News Daily News Cardiac Testing in Chest Pain Patients Without Ischemia Does Not Reduce Acute MI Admissions Michael O'Riordan June 28, 2017
News Industry News Bristol-Myers Squibb and Pfizer Enroll First Patient in Phase 4 AUGUSTUS Trial to Evaluate Safety of Eliquis (apixaban) in Nonvalvular Atrial Fibrillation Patients with a Recent ACS or Undrgoing PCI September 09, 2015